All HHS Contracts — March 27, 2026

60% outlay ($75M) on $125M firm fixed-price order through 2027 signals strong execution and ~$50M remaining commitment.

Full $89M obligation through 2028 for biological sample services, but only 5% outlayed and nonprofit status limits equity upside.

Remaining ~$50M (Empower) and ~$84M (ATCC) obligations vulnerable to delays over 1-2 year horizons amid firm fixed-price and cost-plus terms.

11 subawards ($9M) on Empower contract introduce performance dependencies; full/open competition signals ongoing rivalry.

$5.3M options upside on Empower plus full $214M HHS visibility through 2028 in CMS/BARDA priorities.

BARDA MCM evaluation funding aligns with health preparedness, potentially expanding R&D pipelines.

Concentrated $214M in CMS admin support (60% executed) and BARDA R&D (5% executed) highlights sustained federal priorities through 2028.

{"entity"=>"EMPOWER AI, INC.", "reason"=>"~$50M remaining obligation + $5M options represent 40% untapped value through 2027.", "trigger"=>"outlays exceeding 80% or contract mods"}

{"entity"=>"AMERICAN TYPE CULTURE COLLECTION", "reason"=>"Low 5% outlay on 7-year BARDA award signals cash flow ramp potential.", "trigger"=>"outlays >20% or BARDA budget increases"}